<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00990678</url>
  </required_header>
  <id_info>
    <org_study_id>HH-JEBJ-HIVstudy</org_study_id>
    <secondary_id>EudraCT 2006-005039-40</secondary_id>
    <secondary_id>Danish Health 2612-3303</secondary_id>
    <nct_id>NCT00990678</nct_id>
  </id_info>
  <brief_title>Study of Vitamin D Supplementation to Male HIV Sero-positive Patients</brief_title>
  <official_title>Study of Vitamin D Supplementation to Male HIV Sero-positive Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hvidovre University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hvidovre University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators want to investigate if HIV sero-positive males benefit from vitamin D
      supplementation. The study runs in 16 weeks and the participants are treated with one of
      three placebo controlled regimes (tablets):

        1. Calcium

        2. Calcium and 25-hydroxy-vitamin D

        3. Calcium and 25-hydroxy-vitamin D and 1,25-dihydroxyvitamin D

      The endpoints are:

        -  Serum vitamin D

        -  Parathyroid hormone

        -  ionized calcium

        -  T-lymphocyte fractions (na√Øve, mature, Tregs)

        -  Osteocalcin (bone metabolism)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>serum-vitamin D metabolites</measure>
    <time_frame>week 0</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>serum-vitamin D metabolites</measure>
    <time_frame>week 2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>serum-vitamin D metabolites</measure>
    <time_frame>week 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>serum-vitamin D metabolites</measure>
    <time_frame>week 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>serum-vitamin D metabolites</measure>
    <time_frame>week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>serum-vitamin D metabolites</measure>
    <time_frame>week 16</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>T-lymphocyte fractions Parathyroid hormone ionized calcium</measure>
    <time_frame>week 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T-lymphocyte fractions Parathyroid hormone ionized calcium</measure>
    <time_frame>week 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T-lymphocyte fractions Parathyroid hormone ionized calcium</measure>
    <time_frame>week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T-lymphocyte fractions Parathyroid hormone ionized calcium</measure>
    <time_frame>week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T-lymphocyte fractions Parathyroid hormone ionized calcium</measure>
    <time_frame>week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T-lymphocyte fractions Parathyroid hormone ionized calcium</measure>
    <time_frame>week 16</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>HIV Seropositive</condition>
  <arm_group>
    <arm_group_label>&quot;Strong vitamin D&quot;</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Calcium 400 Mg + Vitamin D3 10 microg, 3 times daily Rocaltrol 1.25 mg to 2.5 mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>calcium 400 mg + 10 microgram Vitamin D3, 3 times daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Calcium</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Tablet Calcium 400 mg x 3 daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rocaltrol</intervention_name>
    <description>tablet, Vitamin 1-OH-D3, total 1.25-2.5 mg daily</description>
    <arm_group_label>&quot;Strong vitamin D&quot;</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D</intervention_name>
    <description>tablets, vitamin D3, 30 microgram daily</description>
    <arm_group_label>&quot;Strong vitamin D&quot;</arm_group_label>
    <arm_group_label>Vitamin D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcium</intervention_name>
    <description>tablets, 400 mg calcium, 3 times daily</description>
    <arm_group_label>&quot;Strong vitamin D&quot;</arm_group_label>
    <arm_group_label>Vitamin D</arm_group_label>
    <arm_group_label>Calcium</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male

          -  HIV-positive

          -  at least 18 years old

          -  receiving HiglyActiveAntiRetroviral Therapy (HAART)

        Exclusion Criteria:

          -  hypercalcemia

          -  tuberculosis

          -  osteoporosis or other bone disease

          -  cancer with bone metastasis
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ulrich C Bang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. of Endocrinology, Hvidovre Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dept. of endocrinology, Hvidovre Hospital</name>
      <address>
        <city>Copenhagen</city>
        <zip>2450</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 6, 2009</study_first_submitted>
  <study_first_submitted_qc>October 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2009</study_first_posted>
  <last_update_submitted>September 13, 2012</last_update_submitted>
  <last_update_submitted_qc>September 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 17, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hvidovre University Hospital</investigator_affiliation>
    <investigator_full_name>Ulrich Bang</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <keyword>HIV-1</keyword>
  <keyword>humans</keyword>
  <keyword>vitamin D</keyword>
  <keyword>1-hydroxy-vitamin D</keyword>
  <keyword>Rocaltrol</keyword>
  <keyword>calcium</keyword>
  <keyword>complementary therapies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Seropositivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Calcitriol</mesh_term>
    <mesh_term>Calcium, Dietary</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

